Author  
Place of duty  
Title   재발성 난소암 환자에서 Triple - Alkylating Regimem 을 이용한 고용량화확요법 및 자가 말초혈액조혈모세포이식 1 예 ( A Case of Triple - Alkylating Regimen and Peripheral Blood Stem Cell Transplantation for a Patient with Relapsed Ovarian Carcinoma )
Publicationinfo   2000 Jan; 032(04): 817-822.
Key_word   Ovary neoplasm, Cyclophosphamide, Melphalan, Thiotepa, Peripheral blood stem cell tranplantation
Full-Text  
Abstract   Despite an aggressive surgical debulking followed by front-line chemotherapy, most patients with advanced ovarian carcinoma die of drug-resistant disease. Drug resistance can be overcome in a subset of patients with hematologic malignancies and lymphoma with high-dose therapy (HDT) and hematopoietic stem cell transplantation, suggesting that this therapy may also be value in ovarian carcinoma. We report the successful outcome of HDT and peripheral blood stem cell transplantation (PBSCT) in a 41-year-old nulliparous woman who initially was diagnosed with advanced ovarian carcicnoma with FIGO stage IIIc. Her disease relapsed after 19 months from initial therapy of definitive surgery and intra- and post-operative chemotherapy. Subsequently, she received optimal debulking surgery and salvage chemotherapy followed by HDT with triple-alkylating regimen, composed of cyclophosphamide (100 mg/kg), thiotepa (500 mg/m), and melphalan (100 mg/m). Her pretranplant characteristics were platinum-sensitive and complete response state. She showed rapid hematologic recovery and mild regimen-related toxicity (Bear- mans toxicity criteria), stomatitis (grade I), cardiac toxicitiy (grade II). She has been followed up for 36 months after the inital therapy and is doing well without relapse.
저 자   이준모(Joon Mo Lee),남궁성은(Sung Eun Namkoong),조석구(Seok Goo Cho),박진노(Jin No Park),홍영선(Young Sun Hong),김훈교(Hoon Kyo Kim),이경식(Kyung Shick Lee),김춘추(Chun Choo Kim)